Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SUNPHARMA

SUN PHARMA.

HealthcarePharmaceuticals & Biotechnology₹449227 cr market cap
₹1912.30 ▲ +2.18% today As of 19 Nov 2026
52-week low ₹1589.3052-week high ₹2001.10

-6.5% from the 52-week high · +17.8% above the low

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra and currently employs 41,000 full-time employees. The firm is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). The company produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The firm's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The firm also has a product portfolio in RoW markets, including injectables, hospital products and retail products. The company offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.

The short version. SUN PHARMA. reported revenue of ₹16,199 crore for Sep 2026, up 11.9% from a year earlier. Net profit was ₹1,989 crore (down 36.2% year on year). Return on equity was 13.7% in Mar 2026. Promoter holding was 52.68% in Sep 2026, down 1.80 points over 8 quarters.

1 · The price

How has the stock traded?

SUN PHARMA. trades 6.5% below its 52-week high and 17.8% above its 52-week low.

Change over period: —

1M+7.4%
3M-1.5%
6M-0.5%
1Y+6.4%

2 · The business

Is it growing?

Sales, year on year+11.9%

Sep 2026 revenue of ₹16,199 cr.

Profit, year on year-36.2%

Sep 2026 net profit of ₹1,989 cr.

Net margin12.3%

9.2 pts lower than a year earlier.

3-year growth10.7% profit

Revenue compounded at 10.7% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1619915300146121552114478138511295913675
Net profit19892895271433693118227921502903
Net margin %12.318.918.621.721.516.516.621.2
EPS (₹)8.2912.0611.3114.0413.09.58.9612.1

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue5846252578484974388638654334983283829066
Net profit1147910929957684743273290437652665
Net margin %19.620.819.719.38.58.711.59.2
EPS (₹)47.8445.5539.9135.3213.6412.115.6911.11

3 · The quality

How well does it turn capital into profit?

Return on equity was 13.7% in Mar 2026; debt to equity is 0.05.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %13.715.115.015.1
Return on capital %17.918.916.515.8
EBITDA margin %30.430.427.927.2
Net margin %19.020.019.219.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR10.7%12.0%
Profit CAGR10.7%31.6%
Debt to equity0.05
Interest cover45.6x
Current ratio2.82
P/E ratio38.9

4 · The owners

Who holds it, and are they adding?

Promoter holding52.68%

Down 1.8 pts over 8 quarters.

Foreign institutions14.36%

Down 3.69 pts over 8 quarters.

Domestic institutions22.27%

Up 3.72 pts over 8 quarters.

Mutual fund schemes519

+97 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter54.4854.4854.4854.4854.4854.4854.4852.68-1.8
FII18.0517.9617.2616.5516.1215.9314.5314.36-3.69
DII18.5518.719.520.2320.8221.1122.1822.27+3.72
Public8.928.878.778.738.588.488.8110.7+1.78

Mutual fund holdings · Oct 2026

519 schemes hold this stock

422 the month before.

  • ICICI Prudential Nifty Pharma ETF18.62% of NAV
  • Nippon India Nifty Pharma ETF18.61% of NAV
  • ICICI Prudential Nifty Pharma Index Fund18.6% of NAV
  • ICICI Prudential Nifty Healthcare ETF16.33% of NAV
  • ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF16.32% of NAV
  • Axis NIFTY Healthcare ETF16.32% of NAV
  • DSP Nifty Healthcare Index Fund16.32% of NAV
  • DSP Nifty Healthcare ETF16.31% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SUN PHARMA. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SUN PHARMA.

What is the SUN PHARMA. share price?

SUN PHARMA. (SUNPHARMA) last closed at ₹1,912.30, up 2.18% on the day. Its 52-week range is ₹1,589.30 to ₹2,001.10.

What is the market cap of SUN PHARMA.?

SUN PHARMA. has a market capitalisation of about ₹449,227 crore. Its price-to-earnings ratio is 38.9.

How are SUN PHARMA.'s latest results?

SUN PHARMA. reported revenue of ₹16,199 crore for Sep 2026, up 11.9% from a year earlier. Net profit was ₹1,989 crore (down 36.2% year on year). Return on equity was 13.7% in Mar 2026. Promoter holding was 52.68% in Sep 2026, down 1.80 points over 8 quarters.

Who owns SUN PHARMA.?

As of Sep 2026, shareholding was: Promoter 52.68%, FII 14.36%, DII 22.27%, Public 10.7%.

How many mutual funds hold SUN PHARMA.?

519 mutual fund schemes held SUN PHARMA. in October 2026. That compares with 422 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 07 Jul 2026 · Final Dividend - Rs. 5
  • 05 Feb 2026 · Interim Dividend - Rs. 11
  • 07 Jul 2025 · Final Dividend - Rs. 5.5
  • 06 Feb 2025 · Interim Dividend - Rs. 10.5
  • 12 Jul 2024 · Final Dividend - Rs. 5
  • 09 Feb 2024 · Interim Dividend - Rs. 8.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.